Table 3.

Comparison of clinical trial combining bevacizumab and radiation in locally advanced head and neck cancer

Study	Patient	Other Chemo Agents	BevacizumabDose	3 Year LRFFS	3 Year PFS	3 Year OS
Salama (16)	17	5 FU, Hydroxyurea	10 mg/kg, every 2 weeks	67% (2 year)	59% (2 year)	58% (2 year)
Fury (17)	42	Cisplatin	15 mg/kg, every 3 weeks		75.9% (2 year)	88% (2 year)
Hainsworth (18)	60	Paclitaxel Erlotinib	15 mg/kg, every 3 weeks		71%	82%
Yoo (19)	29	Cisplatin Erlotinib	10 mg/kg, every 2 weeks	85%	82%	86%
Current study	30	docetaxel	5 mg/kg, every 2 weeks	84.5%	61.7%	68.2%

Abbreviation: LRFFS, local-regional failure free survival; PFS, progression-free survival; OS, overall survival.